Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Cancer Center Division
79 active people
103 grants
Recent Grants
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated
2024
·
$7.5M
immunotherapy,
cancer treatment,
biopharmaceuticals,
clinical trials,
monoclonal antibodies
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent And Combination Therapy In Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
2024
·
$1.6M
cancer,
pharmacokinetics,
drug therapy,
clinical trial,
tumor treatment
A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory C
2024
·
$1.3M
immunotherapy,
cancer treatment,
clinical trial,
pd-(l)1 inhibitors,
combination therapy
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom
2024
·
$1.2M
lymphoma,
efficacy,
safety,
treatment,
clinical trial
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anti-Cancer Therapies in Solid Tumors
2024
·
$724K
cancer,
immunotherapy,
clinical trial,
monotherapy,
combination therapy
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
2024
·
$625.4K
oncology,
clinical trial,
drug combination,
efficacy,
patient safety
Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Stage 4 Metastatic Non-Small Cell Lung Cancer
2024
·
$577.4K
immunotherapy,
radiotherapy,
cancer,
clinical trial,
metastatic
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
2024
·
$548.6K
oncology,
clinical trials,
chemotherapy,
cancer treatment,
targeted therapy
A Phase 1/2 Open-Label, Multicenter, Global Trial to Characterize the Safety, Tolerability and Preliminary Efficacy of CFT1946 as a Monotherapy and in Combination with Trametinib in Subjects with BRAF
2024
·
$433.9K
drug development,
oncology,
clinical trials,
pharmacology,
precision medicine
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
2024
·
$348.6K
oncology,
clinical trials,
immunotherapy,
pharmacology,
drug safety
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for
2024
·
$252.6K
breast cancer,
adjuvant therapy,
immunotherapy,
clinical trial,
hormone receptor
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck S
2024
·
$119.8K
cancer,
immunotherapy,
clinical trial,
head and neck,
pharmacology
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifera
2024
·
$7.5K
clinical trials,
kidney diseases,
drug safety,
immunology,
pharmacology
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
2023
·
$2.1M
clinical trials,
oncology,
pharmacokinetics,
safety,
efficacy
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
2023
·
$825.5K
oncology,
clinical trials,
immunotherapy,
cancer treatment,
drug efficacy
A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)
2023
·
$770.6K
cell therapy,
diabetes,
chronic kidney disease,
clinical trial,
renal therapy
A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors and Subsequent Expansio
2023
·
$735.4K
cancer,
pharmacokinetics,
clinical effects,
intravenous administration,
safety
Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have R
2023
·
$709.8K
breast cancer,
immunotherapy,
clinical trials,
combination therapy,
precision medicine
A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas
2023
·
$684.8K
cancer treatment,
drug trial,
dose escalation,
solid tumors,
lymphomas
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
2023
·
$568.2K
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
People
Ann Bridges
Conference and Events Planner II
AJ Steuer
Research Compliance Administrator I
Aradhana Kari
Research Compliance Administrator II
Alaina Krone
Clinical Research Manager III
Amy Carrier
Research Nurse III
Angelica Erunez
Research Compliance Administrator II
Angelique Thornton
Research Nurse II
Amy Selegue
Clinical Research Manager II
Autumn Lester
Research Technician II
Angela Yung
Researcher/Scientist III
Bryan Clines
Research Compliance Administrator III
Beth Estevez Quintana
Clinical Research Coordinator II
Betsey Wagener
Research Program Administration Manager IV
Brianna Loughran
Clinical Research Coordinator II
Betsy Wertheim
Biostatistician II
Brianna Denton
Research Compliance Manager I
Bethany Skovan
Research Specialist, Senior
Catherine Cordova
Research Professional I
Carole Kepler
Laboratory Coordinator II
Carolyn Lane
Research Laboratory Manager I
Michele Chu-Pilli
Research Program Administration Officer III
Carol Carpenter
Research Development Professional IV
Cyndie Neal
Clinical Research Coordinator II
Daniel Buster
Researcher/Scientist IV
Dakota Hartliep
Research Technician II
Diana Dawson
Research Compliance Administrator II
Claudia Espitia
Researcher/Scientist IV
Francois Chu
Research Compliance Administrator I
Lupita Ramos-Barrera
Clinical Research Manager I
Gillian Paine-Murrieta
Research Laboratory Manager III
Haiyan Cui
Research Specialist, Senior
Jose Guillen-R
Biostatistician II
Jaime Gard
Laboratory Coordinator III
Kai Kau
Clinical Research Coordinator II
Kathleen Molinar
Research Program Administration Officer II
Carmen Arredondo
Administrative Support Assistant I
Laura Duckett
Clinical Research Coordinator III
Lizeth Evangelista
Research Compliance Administrator II
Lora Inclan
Clinical Research Coordinator III
Jepkoech Kimaru
Research Program Administration Officer III
Elizabeth McPeak
Clinical Research Manager IV
Linda Maynard
Research Program Administration Officer I
Liliana Mendivil
Community Outreach Professional II
Maga Sanchez
Research Laboratory Manager I
Namoonga Mantina
Community Outreach Manager I
Marco Padilla-Rodriguez
Researcher/Scientist IV
Mark Febbo
Communications Manager III
Mario Cruz
Research Program Administration Officer II
Michelle Perez-coronado
Community Outreach Professional I
Mitzi Miranda
Research Program Administration Officer III
Mary Krutzsch
Research Specialist, Senior
Michael Yozwiak
Researcher/Scientist III
Michele Holland
Research Compliance Administrator II
Melissa Molina
Research Compliance Administrator II
Maria Prevatt
Research Program Administration Officer IV
Monica Yellowhair
Community Outreach Manager II
Niyuri Fleming
Clinical Research Manager I
Assumpta Nsengiyunva
Laboratory Coordinator I
Octavio Castanos
Research Compliance Administrator II
Camilo Ortiz
Community Outreach Professional I
Prisca Zimmerman
Project Manager III
Patricia Robles Quihuis
Research Nurse III
Ruth Ca?amar
Research Program Administration Officer III
Rebecca Crocker
Research Program Administration Officer II
Rosa Fung
Financial Analysis Manager IV
Debora Aguirre
Administrative Support Assistant III
H-H. Sherry Chow
Research Scientist
Sylvia DeCero
Research Nurse III
Sophia Farrisi
Laboratory Coordinator I
Jaron Solsky
Clinical Research Manager I
Sandra Ortega
Clinical Research Coordinator II
Stephanie Soto
Clinical Research Coordinator III
Sonja Velickovic
Laboratory Coordinator I
Sylvia Paton
Clinical Research Manager III
Teri Bankhead
Administrative Operations Manager V
Tiffanie Cagle
Clinical Research Coordinator II
Thomas Schlabach
Clinical Research Coordinator II
Terri Katz
Research Compliance Administrator I
Wade Chew
Research Technologist III
